Voyager Therapeutics, Inc.
VYGR
$3.77
-$0.18-4.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.45% | -7.61% | 10.05% | -281.32% | 10.82% |
| Total Depreciation and Amortization | -12.49% | 5.03% | 0.30% | -10.69% | -18.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.15% | 15.79% | 74.02% | -11.70% | -57.10% |
| Change in Net Operating Assets | -48.03% | 53.53% | -170.78% | 173.82% | 21.45% |
| Cash from Operations | 6.65% | 12.23% | -160.82% | 48.05% | 11.44% |
| Capital Expenditure | 81.27% | -67.93% | -324.52% | 39.92% | 73.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,055.20% | -92.74% | 254.76% | -141.86% | 284.73% |
| Cash from Investing | 1,704.86% | -95.31% | 251.46% | -142.27% | 279.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.43% | 525.61% | -85.71% | 4,000.00% | -97.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.43% | 525.61% | -85.71% | 4,000.00% | -97.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.74% | -1,009.53% | 108.23% | -213.08% | 154.36% |